Markets Screener Institutions Status About FAQ Insights API

Loading institutional data...

Request data / API access →

Data from SEC EDGAR filings: company financials and 13F holdings.

Disclaimer: QW Research is provided for informational and educational purposes only and is not investment advice, a recommendation, or an offer to buy or sell any security. Data is derived from public SEC 13F filings and may be incomplete, delayed, or inaccurate. Do not make investment decisions based on this content. QW Research does not share in any profits and accepts no liability for any losses or decisions made using this information. Past performance does not predict future results.

QW Research © 2026

DRUG — Fundamentals, Valuation & Ownership | QW Research

Back to Markets

BRIGHT MINDS BIOSCIENCES INC. (DRUG)

Accumulating

Strong institutional accumulation: ownership increased +56.99% quarter-over-quarter.

Data as of Q1 2026

Loading snapshot...

No collected fundamentals to build a valuation model.

No collected fundamentals for a quality & risk analysis.

No collected fundamentals for a dividends & returns analysis.

No collected fundamentals for a capital-allocation analysis.

Loading debt & leverage...

Loading performance...

Loading peer comparison...

Loading ownership map...

Loading crowding analysis...

Loading conviction analysis...

Institutional Ownership

100.0%

of shares outstanding · 89 funds hold it

Ownership Change

56.99 pts

institutions added to their stake last quarter

Crowding

86ᵗʰ pctl

more crowded than 86% of tracked stocks

Institutional Value

$667.7M

total position value across all 13F filers

Loading buy/sell flow...

Loading ownership trends...

Loading top holders...

Institutional Holders

Loading top holders...

No collected fundamentals for a debt & leverage analysis.

Buy / Sell Volume by Quarter

Total shares institutions bought (green) vs sold (red) each quarter across all holders.

Inferred from quarter-over-quarter change in each fund's 13F position (new stakes count as buys, exits as sells). Not tick-level trades.

Loading ownership map...

Loading crowding analysis...

Institutional Trends (8 Quarters)

Conviction-Weighted Ownership

Median weight: 0.39%Avg weight: 1.05%Max: 3.88%High conviction (>1%): 4

JANUS HENDERSON GROUP

Cormorant Asset Management,

ADAGE CAPITAL PARTNERS GP, L.L.C.

Vestal Point Capital,

DRIEHAUS CAPITAL MANAGEMENT

PERCEPTIVE ADVISORS

BALYASNY ASSET MANAGEMENT L.P.

Ownership Map

Top 40 institutional holders — bubble size is position value, color is the move since last quarter. Hover any holder for detail.

Size by

Drag any bubble to rearrange · size = dollar value of the position

Ownership Map

Top 40 institutional holders — bubble size is position value, color is the move since last quarter. Hover any holder for detail.

Size by

Drag any bubble to rearrange · size = dollar value of the position

Crowding AnalysisCrowded

Holders89of 5,944

Avg: 68

Uncrowded86th percentileCrowded

Institutional Activity

Buy/Sell Ratio3.08x

73th percentile

74 buying24 selling

+29

New

-9

Closed

+2.6M

Net shares

Ownership Concentration

Top 5: 44.4%Top 10: 67.3%

JANUS HENDERSON GROUP14.0%

Cormorant Asset Management,11.6%

Vivo Capital,6.1%

Others (84)55.6%

Crowding AnalysisCrowded

Holders89of 5,944

Avg: 68

Uncrowded86th percentileCrowded

Institutional Activity

Buy/Sell Ratio3.08x

73th percentile

74 buying24 selling

+29

New

-9

Closed

+2.6M

Net shares

Ownership Concentration

Top 5: 44.4%Top 10: 67.3%

JANUS HENDERSON GROUP14.0%

Cormorant Asset Management,11.6%

Vivo Capital,6.1%

Others (84)55.6%

Performance vs. S&P 500

Total return (dividends reinvested) vs the market, from quarter-end prices.

$10,000 invested 2021-06

$30,508

DRUG · +205%

$18,666

S&P 500 · +87%

+$11,843

ahead of the index

Total return (5Y)

+205%

S&P 500

+87%

vs. market

+118%

outperformed

Annualized

25.0%

mkt 13.3%

Volatility

1336%

annualized

Beta

-1.95

vs S&P 500

Growth of $10,000

Hover the chart to read any quarter

DRUGS&P 500

Year by year

Annual return vs the market

Hover a year to compare.

DRUG (solid)S&P 500 (outline)Green = positive year, red = negative. Number = DRUG's return.

Beat the market

2 / 6 yrs

33% win rate

Best year

+2419%

2024

Worst year

-77%

2022

Worst drawdown

-97%

recovered in 2 qtrs

Relative strength

Cumulative lead over the S&P 500

Above 0 = ahead of the S&P 500 since the window start; below 0 = behind. Rising means it's pulling ahead.

Downside

Drawdown from peak · max -97%

How far the stock fell below its prior peak. Deeper, longer drawdowns = a rougher ride to the same return.

Quarter-end, dividend-adjusted (total return). Beta & volatility from quarterly returns (annualized). Benchmark is the S&P 500 (SPY total return). Annual returns compound the quarters ending in each calendar year; the first and last years in a window may be partial. Past performance doesn't predict future results.

We haven't collected financials for DRUG yet, so it can't be scored against its Healthcare peers.